Cargando…

Development of Novel Murine BRAF(V600E)-Driven Papillary Thyroid Cancer Cell Lines for Modeling of Disease Progression and Preclinical Evaluation of Therapeutics

SIMPLE SUMMARY: Laboratory experimental models are essential for advancements in thyroid cancer translational research. In this study, we discuss the development and characterization of six cell-based models of BRAF(V600E)-driven papillary thyroid cancer that closely mimic the heterogeneous patholog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Branigan, Grace Purvis, Casado-Medrano, Victoria, O’Neill, Alison B., Ricarte-Filho, Julio C., Massoll, Nicole, Salwen, Madeleine, Spangler, Zachary, Scheerer, Michele, Williamson, Edward K., Bauer, Andrew J., Franco, Aime T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913801/ https://www.ncbi.nlm.nih.gov/pubmed/36765847 http://dx.doi.org/10.3390/cancers15030879

Ejemplares similares

OR09-4 Novel Murine Models of BrafV600E driven Papillary Thyroid Cancer
por: Casado Medrano, Victoria, et al.
Publicado: (2022)

Clinical implication of the BRAF(V600E) mutation in papillary thyroid carcinoma
por: Kim, Yong-Seok, et al.
Publicado: (2013)

Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma
por: HE, GUOPING, et al.
Publicado: (2014)

BRAF V600E and lymph node metastases in papillary thyroid cancer
por: Chen, Pan, et al.
Publicado: (2020)

DICER1 RNase IIIb domain mutations trigger widespread miRNA dysregulation and MAPK activation in pediatric thyroid cancer
por: Ricarte-Filho, Julio C., et al.
Publicado: (2023)

Preclinical Evaluation of Vemurafenib as Therapy for BRAF(V600E) Mutated Sarcomas
por: Gouravan, Sarina, et al.
Publicado: (2018)

Restoring Radioiodine Uptake in BRAF V600E–Mutated Papillary Thyroid Cancer
por: Huillard, Olivier, et al.
Publicado: (2017)

Relationship between BRAF V600E and clinical features in papillary thyroid carcinoma
por: Yan, Changjiao, et al.
Publicado: (2019)

Risk and Prognostic Factors for BRAF(V600E) Mutations in Papillary Thyroid Carcinoma
por: Wei, Xiaojing, et al.
Publicado: (2022)

Sacral metastases in a patient with BRAF V600E+ papillary thyroid carcinoma
por: Bhethanabotla, Rohith M, et al.
Publicado: (2023)

The BRAF(V600E) mutation analysis and risk stratification in papillary thyroid carcinoma
por: Scheffel, Rafael Selbach, et al.
Publicado: (2020)

Prevalence of BRAF(V600E) Mutation in Follicular Variant of Papillary Thyroid Carcinoma and Non-Invasive Follicular Tumor with Papillary-Like Nuclear Features (NIFTP) in a BRAF(V600E) Prevalent Area
por: Kim, Hyereen, et al.
Publicado: (2018)

The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors
por: Choi, Sun Yi, et al.
Publicado: (2013)

Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib
por: Ali, Siraj M., et al.
Publicado: (2014)

BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients
por: Sun, Jian, et al.
Publicado: (2016)

Correlation between Ultrasonographic Appearance of Papillary Thyroid Microcarcinoma and BRAF V600E Mutation
por: Liang, Songnian, et al.
Publicado: (2022)

Comparative BRAF V600E immunohistochemical expression in differentiated thyroid tumors with papillary features
por: Wahid, Maha Hatem Abdul, et al.
Publicado: (2022)

Detection of Plasma BRAF(V600E) Mutation Is Associated with Lung Metastasis in Papillary Thyroid Carcinomas
por: Kim, Bo Hyun, et al.
Publicado: (2015)

Association between the BRAF V600E mutation and ultrasound features of the thyroid in thyroid papillary carcinoma
por: Li, Qian, et al.
Publicado: (2017)

Association between BRAF(V600E) mutation and the clinicopathological features of solitary papillary thyroid microcarcinoma
por: Lu, Hai-Zhen, et al.
Publicado: (2017)

The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer
por: Ge, Junshang, et al.
Publicado: (2020)

Clinical Significance of PEAK1 Expression and BRAF V600E Mutation in Papillary Thyroid Cancer
por: Li, P., et al.
Publicado: (2022)

The Prognostic Implication of the BRAF V600E Mutation in Papillary Thyroid Cancer in a Chinese Population
por: Ye, Ziheng, et al.
Publicado: (2022)

Risk Factors for Neck Nodal Metastasis in Papillary Thyroid Cancer With BRAF V600E Mutation
por: Han, Ying, et al.
Publicado: (2022)

BRAF(V600E) Positivity-Dependent Effect of Age on Papillary Thyroid Cancer Recurrence Risk
por: Park, Joonseon, et al.
Publicado: (2023)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

Shifted termination assay (STA) fragment analysis to detect BRAF V600 mutations in papillary thyroid carcinomas
por: Kang, So Young, et al.
Publicado: (2013)

Immunohistochemistry cannot replace DNA analysis for evaluation of BRAF V600E mutations in papillary thyroid carcinoma
por: Szymonek, Monika, et al.
Publicado: (2017)

Simultaneous Hodgkin lymphoma and BRAF(V600E)-positive papillary thyroid carcinoma: A case report
por: Liu, Shu, et al.
Publicado: (2019)

Snail-1 Overexpression Correlates with Metastatic Phenotype in BRAF(V600E) Positive Papillary Thyroid Carcinoma
por: Wieczorek-Szukala, Katarzyna, et al.
Publicado: (2020)

Incidence of BRAF V600E mutation in patients with papillary thyroid carcinoma: a single-institution experience
por: Kure, Shoko, et al.
Publicado: (2019)

Prognostic Significance of BRAF V600E Mutation and CPSF2 Protein Expression in Papillary Thyroid Cancer
por: Ivković, Irena, et al.
Publicado: (2022)

MRI-Based Texture Analysis for Preoperative Prediction of BRAF V600E Mutation in Papillary Thyroid Carcinoma
por: Zheng, Tingting, et al.
Publicado: (2023)

Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report
por: Rao, Mayank, et al.
Publicado: (2019)

Papillary thyroid cancer organoids harboring BRAF(V600E) mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies
por: Chen, Dong, et al.
Publicado: (2023)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

Addendum: Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report
por: Rao, Mayank, et al.
Publicado: (2023)

Clinical Outcome, Role of BRAF(V600E), and Molecular Pathways in Papillary Thyroid Microcarcinoma: Is It an Indolent Cancer or an Early Stage of Papillary Thyroid Cancer?
por: Nucera, Carmelo, et al.
Publicado: (2012)

Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_7qvot4j5v1p13f5e1h5lgo6r4l